This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -5.56% and 10.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0.00% and 85.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Ocular Therapeutix Sees Hammer Chart Pattern: Time to Buy?
Ocular Therapeutix (OCUL) Enters Oversold Territory
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on a bit of a cold streak lately
Can the Rally in Ocular Therapeutix (OCUL) Shares Continue?
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) has been on the move lately as the stock has risen by 38% in the past four weeks, and it is currently trading well above its 20-Day SMA
Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
by Zacks Equity Research
Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.